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Abstract
Tumor blood supply was related to the morphology of the tumor microvasculature and the supplying arteries (SAs)
of A-07-GFP and D-12-GFP melanoma xenografts growing in window chamber preparations in BALB/c nu/nu mice.
Blood supply and morphologic parameters were determined from first-pass imaging movies and vascular maps re-
corded after a bolus of 155-kDa tetramethylrhodamine isothiocyanate–labeled dextran had been administered in-
travenously. Poorly supplied tumors showed microvascular networks that did not differ from those of well-supplied
tumors in vessel tortuosity, diameter, and density. Conversely, the SAs of poorly supplied tumors were more tor-
tuous and had a smaller diameter than those of well-supplied tumors, resulting in lower plasma velocities in the
downstream tumor vessels. Consequently, the blood supply of A-07-GFP and D-12-GFP tumors was governed by
the geometric resistance of the SAs rather than by the geometric resistance or the vessel density of the tumor
microvasculature. The present study suggests that the SAs may represent an important target for physiological
interventions of tumors and that it may be beneficial to focus on the tumor SAs rather than the tumor microvas-
culature when searching for novel therapeutic strategies for modifying tumor blood supply.
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Introduction
The physiological microenvironment of experimental and human tu-
mors is distinctly different from that of normal tissues [1]. Tumors
develop a highly heterogeneous microenvironment during growth,
characterized by oxygen depletion, extracellular acidosis, elevated
lactate levels, glucose deprivation, low energy status, and interstitial
hypertension [2]. This hostile microenvironment causes resistance to
treatment [3] and may promote malignant progression, invasive
growth, and metastatic dissemination [4]. The physiological param-
eters of the tumor microenvironment are determined mainly by the
blood supply, and the blood supply depends primarily on the vascular
density, the geometric resistance to blood flow, and the viscosity of
the blood [1,2,5,6].
The rate of blood flow in any vessel segment is proportional to the
pressure difference between the arterial and venous sides and is in-
versely proportional to the viscous and geometric resistances [2,6].
When laminar flow through a circular, rigid tube can be assumed,
the geometric resistance of a vessel segment is proportional to the seg-
ment length and inversely proportional to the segment diameter to
the fourth power [6]. The diameter is thus the major determinant of
geometric resistance in this simplified model. Tumor vessel segments,
however, show severe morphologic abnormalities and are rarely cir-
cular rigid tubes. The morphologic abnormalities include contour ir-
regularities (lacunalike, sinusoidal, and cystiform vessels), tortuosity
(distorted, twisted, and bent vessels), and suboptimal dimensions (di-
lated and elongated vessels) [2], and the geometric resistance of tu-
mor vessel segments is increased by contour irregularities and vessel
tortuosity [2,7].
The geometric resistance of a network of vessels is a complex func-
tion of the geometric resistance of the individual vessel segments and
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the overall architecture of the network [6]. Tumor tissues develop vas-
cular networks with severe architectural abnormalities, including lim-
ited arterial supply, heterogeneous vessel distribution, absent vessel
hierarchy, increased intervessel distances, arteriovenous shunts, ex-
cessive branching, and blind vascular ends [2,3,8]. The fractal di-
mensions of tumor microvascular networks have been shown to
correspond closely to those produced by a statistical growth process
known as invasion percolation [7]. Invasion percolation models the
expansion of a network throughout a medium with randomly dis-
tributed heterogeneities in strength. The resulting network always ex-
pands into the weakest available sites, yielding a network with highly
heterogeneous density and vascular pathways that are tortuous over
many scales [7,9]. Calculations have indicated that the highly hetero-
geneous networks produced by invasion percolation have a higher re-
sistance to flow than more regular networks [10]. The microvascular
network of tumors is thus expected to show elevated geometric resis-
tance to blood flow because of the abnormal architecture [2,7,9,11].
Experimental studies making use of ex vivo perfusion techniques
have confirmed that the geometric resistance to blood flow is signif-
icantly higher in tumors than in normal tissues [12,13], and several
morphologic and architectural parameters influencing the geometric
resistance of tumor microvascular networks have been identified and
quantitated [2,7,9,11,13]. Conversely, the significance of the geo-
metric resistance of the arteries supplying tumors with blood has
not been studied thus far. In the present work, tumors growing in
mouse dorsal window chambers were subjected to detailed examina-
tions of blood supply, vessel morphology, and vascular architecture.
The intertumor heterogeneity in blood supply in human melanoma
xenografts was found to be determined primarily by the geometric resis-
tance of the tumor supplying arteries (SAs) rather than by the geometric
resistance or the vessel density of the tumor microvascular network.
Materials and Methods
Mice
Adult (8-10 weeks of age) female BALB/c nu/nu mice, bred and
maintained as described elsewhere [14], were used as host animals for
dorsal window chamber preparations. The animal experiments were
approved by the institutional committee on research animal care and
were done according to the Interdisciplinary Principles and Guide-
lines for the Use of Animals in Research, Marketing, and Education
(New York Academy of Sciences, New York, NY).
Cells and Multicellular Spheroids
A-07 and D-12 human melanoma cells [15] were constitutively
transfected with green fluorescence protein (GFP) by lipofection. The
transfected cells (A-07-GFP and D-12-GFP) were grown as mono-
layers in RPMI 1640 (25 mMHEPES and L-glutamine) supplemented
with 13% bovine calf serum, 250 μg/ml penicillin, 50 μg/ml strep-
tomycin, and 700 μg/ml (A-07-GFP) or 900 μg/ml (D-12-GFP) ge-
netecin. Multicellular spheroids were produced and maintained by
using a liquid-overlay culture technique [16]. Cell and spheroid cul-
tures were incubated at 37°C in a humidified atmosphere of 5%
CO2 in air and were subcultured twice a week.
Anesthesia
Window chamber implantation and intravital microscopy exami-
nations were carried out with anesthetized mice. Fentanyl citrate
(Janssen Pharmaceutica, Beerse, Belgium), fluanisone (Janssen Phar-
maceutica), and midazolam (Hoffmann-La Roche, Basel, Switzer-
land) were administered intraperitoneally (i.p.) in doses of 0.63,
20, and 10 mg/kg, respectively. After surgery, the mice were given
buprenorphine (Temgesic; Schering-Plough, Brussels, Belgium) i.p.
in a dose of 0.12 mg/kg.
Window Chamber Preparations
Window chambers were implanted into the dorsal skin fold as de-
scribed previously [17]. Briefly, the chamber consisted of two parallel
frames, and after implantation, the frames sandwiched an extended
double layer of skin. Before the chamber was implanted, a circular
hole with a diameter of ∼6.0 mm was made in one of the skin layers.
A plastic window with a diameter of 6.0 mm was attached to the
frame on the surgical side with a clip to provide visual access to
the fascial side of the opposite skin layer. Tumors were initiated by
implanting A-07-GFP or D-12-GFP spheroids with a diameter of
100 to 200 μm onto the fascial side of the intact skin layer.
Intravital Microscopy
The mice were kept in a specially constructed holder that fixed the
window chamber to the microscope stage during intravital micros-
copy. The body core temperature was kept at 37 to 38°C by using
a hot air generator. Imaging was performed by using an inverted fluo-
rescence microscope equipped with filters for green and red lights
(IX-71; Olympus, Munich, Germany), a black and white CCD cam-
era (C4742-95; Hamamatsu Photonics, Hamamatsu, Japan), and an
appropriate image acquisition software (Wasabi; Hamamatsu Photon-
ics). Tetramethylrhodamine isothiocyanate–labeled dextran (TRITC-
dextran) with a molecular weight of 155 kDa (Sigma Aldrich, St.
Louis, MO) was used as vascular tracer. A 0.2-ml bolus of TRITC-
dextran (50 mg/ml) was injected into the lateral tail vein, and first-pass
imaging movies were recorded at a frame rate of 18 frames per second
(fps) by using a ×1.25 objective lens, resulting in a time resolution of
55.6 milliseconds, a field of view of 6.89 × 5.51 mm2, and a pixel size
of 10.8 × 10.8 μm2. Afterward, the entire vascular network was
mapped by recording 9 to 16 single frames with a ×4 objective lens,
resulting in a field of view of 2.15 × 1.72 mm2 and a pixel size of 3.4 ×
3.4 μm2. To investigate the reproducibility, A-07-GFP tumors were
subjected to imaging twice. In these experiments, 0.05-ml boluses of
TRITC-dextran (80 mg/ml) were injected, and first-pass imaging
movies were recorded at a frame rate of 9 fps. All recordings were
stored and analyzed offline.
Data Analysis
Two two-dimensional projected vascular masks were produced for
each tumor (i.e., pixels within and outside the network were given the
value of 1 and 0, respectively), one from the movies recorded with
the ×1.25 objective and the other from the images recorded with
the ×4 objective [18]. Blood supply time (BST) images were produced
by assigning a BST value to each pixel of the low-magnification vas-
cular masks. The BST of a pixel was defined as the time difference
between the frame showing maximum fluorescence intensity in the
pixel and the frame showing maximum fluorescence intensity in the
main tumor SA, as described in detail previously [14]. Plasma veloci-
ties in vessel segments were calculated from the time lag in maximum
fluorescence intensity along the segments [14]. The diameter and
tortuosity of the tumor SAs were assessed from single frames of the
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first-pass imaging movies. The morphologic parameters of the tumor
microvasculature were assessed from the high-magnification images
and vascular masks. Vessel tortuosity (T ) was defined as T (%) =
(SL − S) · 100/SL, where SL represents the segment length (the dis-
tance between the branching points along the vessel) and S represent
the shortest distance between the branching points (the distance be-
tween the branching points along a straight line). Median tortuosity
of a vascular network was calculated from ∼100 randomly selected ves-
sel segments. Vascular area fraction [no. of pixels (vascular mask)/no. of
pixels (tumor)] and median vessel diameter were calculated as de-
scribed earlier [18].
Statistical Analysis
The Spearman rank order correlation test was used to search for
correlation between parameters. Statistical comparisons of data were
carried out by nonparametric analysis using the Mann-Whitney rank
sum test. Probability values of P < .05, determined from two-sided
tests, were considered significant. The statistical analysis was per-
formed by using the SigmaStat statistical software (SPSS Science,
Chicago, IL).
Results
Sensitivity of the BST Assay
Three single frames from a representative first-pass imaging movie
of an A-07-GFP tumor (encircled ) are presented in Figure 1A. The
first frame refers to the point of time when the TRITC-dextran bolus
reached the main SA. The second frame was recorded ∼0.56 seconds
after the first frame, and at that time, the bolus had reached most of
the tumor capillaries. The third frame was recorded ∼1.67 seconds
after the first frame and highlights some tumor venules (TVs) filled
with TRITC-dextran. The graph shows relative fluorescence inten-
sity versus time for a region of interest in the main SA and for single
Figure 1. (A) Three single frames from a representative first-pass imaging movie of an A-07-GFP tumor (encircled in white), and relative
fluorescence intensity versus time for a region of interest in the main SA (black curve) and for single pixels in a TA (red curve) and a TV
(green curve). The first frame refers to the point of time when the TRITC-dextran bolus reached the main SA. The second and the third
frames were recorded 0.56 and 1.67 seconds after the first frame, when the bolus had reached most of the capillaries and most of the
venules, respectively. (B, C) Blood supply time images and the corresponding BST frequency distributions derived from two imaging
sessions of two A-07-GFP tumors differing in median BST (vertical lines), illustrating the reproducibility of the BST assay. Color bars, BST
scale; scale bars, 1 mm.
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pixels in a tumor arteriole (TA) and a TV. Curves showing a well-
defined peak were obtained for all vessel types in the tumors. The
position of the peak differed among the vessels and reflected the time
arterial blood needed to reach the different vessels. Accurate BST val-
ues could be determined for single pixels, and high-resolution BST
images could be produced. Examinations of BST images (Figures 1,
B and C , and 2, A and B) showed that the BST value changed grad-
ually along vessel segments without discontinuities.
Reproducibility of the BST Assay
To investigate the reproducibility of the BST assay, A-07-GFP tu-
mors were subjected to first-pass imaging twice, with 20-minute in-
tervals between the imaging sessions. The assay was found to be
highly reproducible, as illustrated in Figure 1, B and C , which show
the BST images and frequency distributions of two tumors differing
in median BST. The intratumor heterogeneity in BST seen in the
first image was reproduced in the second image (i.e., almost all ves-
sel segments have the same color in the two images). The BST fre-
quency distributions of the two tumors were significantly different,
both in the first (P < .0001) and the second (P < .0001) imaging
sessions, whereas the BST frequency distributions obtained in the
two imaging sessions were not significantly different for any of the
tumors (P > .05).
Individual Tumors Differ in BST
Blood supply time differed substantially among individual tumors,
as illustrated in Figure 2, which shows the BST image and the
corresponding BST frequency distribution of an A-07-GFP tumor
with low BST values (Figure 2A, left), an A-07-GFP tumor with high
BST values (Figure 2A, right), a D-12-GFP tumor with low BST val-
ues (Figure 2B, left), and a D-12-GFP tumor with high BST values
(Figure 2B, right). Median BSTof all tumors included in the study is
Figure 2. (A) Blood supply time image and the corresponding BST frequency distribution of an A-07-GFP tumor with low median BST
(left) and an A-07-GFP tumor with high median BST (right). (B) Blood supply time image and the corresponding BST frequency distribu-
tion of a D-12-GFP tumor with low median BST (left) and a D-12-GFP tumor with high median BST (right). Color bars, BST scale; scale
bars, 1 mm; vertical lines, median BST. (C) Median BST of A-07-GFP and D-12-GFP tumors. Points, individual tumors; dashed line, BST =
1.5 seconds, separating the tumors with low median BST from those with high median BST. (D) Area of A-07-GFP and D-12-GFP tumors
with median BST < 1.5 seconds (open symbols) and A-07-GFP and D-12-GFP tumors with median BST > 1.5 seconds (closed symbols).
Points, individual tumors; horizontal lines, mean tumor area.
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shown in Figure 2C , illustrating that most of the tumors showed
BST frequency distributions with median values <1.5 seconds. How-
ever, 3 of the 9 A-07-GFP tumors and 3 of the 12 D-12-GFP tu-
mors showed significantly higher median BST values than the other
tumors (P = .024 for A-07-GFP; P = .016 for D-12-GFP). Conse-
quently, the plot in Figure 2C shows a clear gap among the 6 tumors
with the highest BST values and the 15 tumors with the lowest BST
values. On the basis of this observation, the tumors were divided into
subgroups: those with a median BST above the gap and those with a
median BST below the gap [i.e., tumors with low median BST (me-
dian BST < 1.5 seconds) and tumors with high median BST (median
BST > 1.5 seconds)]. The size of the tumors is shown in Figure 2D,
illustrating that two of the A-07-GFP tumors with high median BST
were small and one was large compared with the A-07-GFP tumors
with low median BST, whereas the three D-12-GFP tumors with
high median BST did not differ in size from the nine D-12-GFP
tumors with low median BST (P > .05). Taken together, these ob-
servations suggest that the intertumor differences in BSTwere not a
consequence of differences in tumor size.
High Median BST Correlates with Low Plasma Velocity in
Tumor SAs, TAs, and TVs
To identify the causes of the intertumor heterogeneity in BST, the
plasma velocity was measured in all tumor SAs, three TAs, and three
TVs. As illustrated in Figure 1A, the tumor SAs were located in the
normal tissue surrounding the tumors, whereas the TAs and TVs
were located within the tumor mass. The plasma velocity decreased
gradually from the SAs to the venules, and was higher for the tumors
with low median BST than for the tumors with high median BST,
regardless of tumor line and vessel type (Figure 3). Interestingly, the
difference in plasma velocity between the tumors with low and high
median BST was highest for the tumor SAs [i.e., 6.8-fold (P =
.023; A-07-GFP) and 4.1-fold (P = .016; D-12-GFP); Figure 3A],
second highest for the TAs [i.e., 5.3-fold (P < .0001; A-07-GFP)
and 3.9-fold (P < .0001; D-12-GFP); Figure 3B], and lowest for
the TVs [i.e., 1.6-fold (P = .071; A-07-GFP) and 2.5-fold (P =
.0014; D-12-GFP); Figure 3C ].
The SAs of Tumors with High BST Show High Geometric
Resistance to Blood Flow
The arteries supplying the tumors with high median BST were
highly tortuous compared with those supplying the tumors with
low median BST. This is illustrated qualitatively in Figure 4, which
shows a single frame from the first-pass imaging movie of an A-07-
GFP tumor with low median BST (Figure 4A), an A-07-GFP tumor
with high median BST (Figure 4B), a D-12-GFP tumor with low
median BST (Figure 4C ), and a D-12-GFP tumor with high median
BST (Figure 4D). Quantitative studies showed that the tortuosity of
the SAs was higher for the tumors with high median BST than for
the tumors with low median BST (P = .024, A-07-GFP; P = .016,
D-12-GFP; Figure 5A) and that the diameter of the SAs was smaller
for the tumors with high median BST than for the tumors with low
median BST (P = .095, A-07-GFP; P = .016, D-12-GFP; Figure 5B).
Moreover, there were significant correlations between median BST
and the tortuosity of the SAs (P < .0001; Figure 5C ) and between
median BST and the diameter of the SAs (P = .0080; Figure 5D).
Qualitative or quantitative differences between A-07-GFP and D-
12-GFP tumors were not detected.
Median BST Is Not Correlated to the Geometric Resistance or
the Vessel Density of the Tumor Microvascular Network
To study possible causes of the intertumor heterogeneity in BST
further, median vessel tortuosity, median vessel diameter, and vascu-
lar area fraction were measured within the tumor microvascular net-
works. In contrast to the tumor SAs, the microvascular networks of
Figure 3. Plasma velocity in the SAs (A), TAs (B), and TVs (C) of A-
07-GFP and D-12-GFP tumors with median BST < 1.5 seconds
(open columns) and of A-07-GFP and D-12-GFP tumors with median
BST > 1.5 seconds (filled columns). Columns and bars, mean ± SE
of 8 to 27 vessels from three to nine tumors.
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the tumors with high and low median BST did not differ in vessel
tortuosity (Figure 6A), vessel diameter (Figure 6B), or vascular area
fraction (mean ± SE of 0.409 ± 0.006 vs 0.408 ± 0.017).
Discussion
Blood supply time and the plasma velocity of individual vessels
were measured in window chamber preparations by using a novel
first-pass imaging method [14,17,18]. The main advantage of the
method is that the entire vascular network of transplanted tumors
and the surrounding normal tissue can be examined at high spatial
and temporal resolution in a single imaging sequence. The resolu-
tions used here were sufficiently high to allow identification of most
of the vessels, to measure the plasma flow velocity in the vessels, and
to compute high-quality BST images. By combining this first-pass
imaging method with high-resolution mapping of the microvascular
network, novel studies of possible relationships between tumor blood
supply and vascular morphology were possible.
By subjecting the same preparations to first-pass imaging twice,
the BST assay was found to be highly reproducible. High reproduc-
ibility required that the physiological conditions of the host mice
were not influenced significantly by the experimental procedure. Sta-
ble physiological conditions were achieved by keeping the body core
temperature at 37 to 38°C with a hot air generator and using anes-
thetic doses verified not to alter tumor blood perfusion. Moreover,
the volume of the TRITC-dextran bolus was minimized to avoid per-
turbing the systemic blood pressure. To examine whether the phys-
iological conditions were influenced by the experimental procedure,
the plasma flow velocity was measured retrospectively in a normal
tissue reference vessel, as described by Brurberg et al. [17].
Most tumors develop an abnormal and hostile physiological mi-
croenvironment, primarily because of inadequate blood supply [2].
The inadequate blood supply has been attributed to low and hetero-
geneous microvascular density and high geometric resistance to blood
flow in the tumor microvascular network [6,7]. A novel factor influ-
encing tumor blood supply was identified in the present work. Our
study revealed that the morphology of the tumor SAs may differ con-
siderably among individual tumors growing in the same type of nor-
mal tissue and showed unequivocally that the blood supply of tumors
is influenced significantly by the geometric resistance of these vessels.
Xenografted tumors of two melanoma lines were studied, and al-
though the tumor-initiating spheroids were placed at approximately
the same site relative to the preexisting vascular network in all cham-
bers, significant intertumor heterogeneity in BST, and hence in blood
supply, was seen in both lines. Moreover, the morphology of the
SAs differed significantly among individual tumors, although they
were located in the same type of normal tissue. The SAs of the tumors
with low blood supply were more tortuous and had a smaller diameter
than those of the tumors with high blood supply. High geometric re-
sistance in the SAs correlated with low plasma velocity in these and the
Figure 4. Single frames from first-pass imaging movies of an A-07-GFP tumor with low median BST (A), an A-07-GFP tumor with high
median BST (B), a D-12-GFP tumor with low median BST (C), and a D-12-GFP tumor with high median BST (D), illustrating the position of
the tumor (encircled in white) and the morphology of the tumor SAs. Scale bars, 1 mm.
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downstream vessels. Conversely, the microvascular networks of the tu-
mors with high or low blood supply did not differ significantly in ves-
sel tortuosity, diameter, and density. Consequently, the differences in
blood supply between individual A-07-GFP and D-12-GFP tumors
were primarily a consequence of differences in the geometric resistance
of the SAs rather than differences in the geometric resistance or the
vessel density of the tumor microvascular network.
Although the tumors were initiated from spheroids of approxi-
mately the same size in genetically identical mice, the morphology
of the SAs differed significantly among individual tumors of the same
line. These morphologic differences were most likely a result of sto-
chastic processes as well as local variations in the concentration of
proangiogenic and antiangiogenic factors secreted by the spheroids.
A large number of angiogenesis activators and inhibitors have been
identified [19], and it has been suggested that blood vessels may re-
spond to some angiogenic factors by increasing the vessel diameter
and to others by increasing the vessel length and tortuosity [20]. It
has also been reported that antiangiogenic treatment of tumors may
result in the emergence of tumor vessels with reduced leakiness, di-
ameter, and tortuosity, a phenomenon termed tumor vessel normal-
ization [21]. Interestingly, A-07-GFP and D-12-GFP tumors differ
significantly in angiogenic profile. Thus, A-07-GFP tumors show
high secretion of vascular endothelial growth factor A and interleu-
kin 8, whereas D-12-GFP tumors show high interleukin 8 secretion
and low vascular endothelial growth factor A secretion [22]. In ad-
dition, A-07-GFP tumors show an upregulated expression of the
proangiogenic factors basic fibroblast growth factor and platelet-
derived endothelial cell growth factor [22], and D-12-GFP tumors
show a significant secretion of the antiangiogenic factor thrombo-
spondin 1 [23].
High geometric resistance to blood flow in the SAs may influence
the physiological microenvironment of tumors significantly. As dem-
onstrated here, tumors with tortuous and narrow SAs show reduced
plasma velocities in the downstream tumor vessels and, hence, en-
hanced BST values. Tumors with high BST values may have a partic-
ularly poor overall oxygen supply, and in addition, the PO2 distribution
may differ from those with lower BST values [14,17]. Thus, theoret-
ical and experimental studies have suggested that low blood velocities
in tumors may result in enhanced oxygen extraction at the arterial end
of the microvasculature, rapid oxygen depletion of the erythrocytes,
steep longitudinal PO2 gradients, and a large fraction of vessel segments
with oxyhemoglobin saturations close to zero [24–28]. Tumors having
SAs with high geometric resistance to blood flow may therefore be par-
ticularly aggressive and resistant to treatment.
Several strategies have been used in an attempt to improve the oxy-
genation of tumors, including the use of chemical or physical agents
Figure 5. Mean tortuosity (A) and mean diameter (B) of the SAs of A-07-GFP and D-12-GFP tumors with median BST < 1.5 seconds
(open columns) and A-07-GFP and D-12-GFP tumors with median BST > 1.5 seconds (filled columns). Columns and bars, mean ± SE of
the mean values of three to nine tumors. (C, D) Median BST versus mean tortuosity (C) and mean diameter (D) of the SAs of A-07-GFP
(circles) and D-12-GFP (triangles) tumors. Points, single tumors; lines, curves fitted to the data by regression analysis.
Neoplasia Vol. 11, No. 3, 2009 Tumor Blood Supply Gaustad et al. 283
to increase tumor blood flow, the use of chemical or physiological
methods to increase the oxygen-carrying capacity of the blood, and
the use of antiangiogenic agents to normalize the tumor microvascu-
lature [29–32]. The common feature of these strategies is that they
all focus on the microvessels within tumors and not on the tumor
SAs in the normal tissue surrounding the malignant tissue. The study
reported here suggests that it may be beneficial to focus on the tu-
mor SAs rather than the tumor microvasculature when searching for
therapeutic strategies for improving the blood supply, and hence, the
oxygenation status of tumors. Furthermore, the tumor SAs may rep-
resent an interesting target for physiological interventions attempting
to decrease tumor blood supply, and hence to increase the extent of
tumor hypoxia, to enhance the efficacy of therapeutic strategies de-
veloped to exploit the existence of hypoxic regions in tumors (e.g.,
strategies involving the use of hypoxia-selective cytotoxins or gene
therapy activated by hypoxia) [3].
In conclusion, the present study shows that differences in blood
supply between individual A-07-GFP and D-12-GFP tumors grow-
ing in the mouse dorsal window chamber are primarily a conse-
quence of differences in the geometric resistance of the tumor SAs
(i.e., differences in vessel tortuosity and diameter) rather than differ-
ences in the geometric resistance or density of the tumor microvas-
cular network. Therefore, the tumor SAs may represent an important
novel target for physiological interventions attempting to modify tu-
mor blood supply to enhance the efficacy of established and experi-
mental cancer treatments.
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